Syros Pharmaceuticals Inc
Syros Pharmaceuticals Inc logo
SYRS

Syros Pharmaceuticals Inc (SYRS)

$4.51.81%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.37
Day's Range
$4.59
$3.02
52-Week Range
$21.9
1 month return31.96%
3 month return10.36%
1 year return77.27%
5 year return95.79%

Analyst Recommendation

based on 12 analysts ratings

Buy
91%
Buy
8%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for Syros Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 642.22%

Current

$4.5

Target

$33.4

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization92.8M
Book Value$6.39
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.55
PEG Ratio0.0
Wall Street Target Price33.4

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)0.58
Enterprise Value-105674093
Enterprise Value/Revenue2.58
Enterprise Value/Ebitda0.99

Technicals

Beta1.44
50 Day MA3.85
200 Day MA6.89

Institutional Holdings

Artal Group S A

7.24%

Bain Capital Life Sciences Investors, LLC

5.35%

Flagship Ventures Management, Inc.

4.91%

Avidity Partners Management LP

4.45%

Ally Bridge Group (NY) LLC

4.29%

Adage Capital Partners Gp LLC

3.57%

Company Information

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
OrganizationSyros Pharmaceuticals Inc
Employees124
CEODr. Nancy A. Simonian M.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Syros Pharmaceuticals Inc share price today?

Can Indians buy Syros Pharmaceuticals Inc shares?

How can I buy Syros Pharmaceuticals Inc shares from India?

Can Fractional shares of Syros Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Syros Pharmaceuticals Inc stocks?

What are today’s High and Low prices of Syros Pharmaceuticals Inc?

What are today’s traded volumes of Syros Pharmaceuticals Inc?

What is today’s market capitalisation of Syros Pharmaceuticals Inc?

What is the 52 Week High and Low Range of Syros Pharmaceuticals Inc?

How much percentage Syros Pharmaceuticals Inc is down from its 52 Week High?

How much percentage Syros Pharmaceuticals Inc is up from its 52 Week low?

What are the historical returns of Syros Pharmaceuticals Inc?

Who is the Chief Executive Officer (CEO) of Syros Pharmaceuticals Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*